Jose Guanzon
Internal Medicine · San Jose, CANPI 1134150881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 629 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,645 and has fallen 70.6% since, to $1,955 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $39.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$3K
- AbbVie$2K
- Johnson & Johnson$2K
- Boehringer Ingelheim$2K
- GSK$2K
- plus $12K from 41 others
What the payments were for
- Speaking & faculty fees$1,1195%
- Travel & lodging$230%
- Food & beverage$23,63095%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,786 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $16,770 |
| Pioglitazone Hcl | 31 | $590 |
| Atorvastatin Calcium | 47 | $540 |
| Rosuvastatin Calcium | 29 | $402 |
| Amlodipine Besylate | 54 | $369 |
| Losartan Potassium | 23 | $291 |
| Metoprolol Succinate | 20 | $273 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $263 |
| Valsartan | 11 | $220 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 17 | $212 |
| Finasteride | 11 | $180 |
| Metformin Hcl | 19 | $154 |
| Alendronate Sodium | 12 | $119 |
| Glimepiride | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,713 | $16,77026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Jose
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.